Cargando…
Dithranol as novel co-adjuvant for non-invasive dermal vaccination
Transcutaneous immunization (TCI) utilizing the TLR7 agonist imiquimod (IMQ-TCI) induces T cell-driven protective immunity upon application onto intact skin. In our present work, we combine the anti-psoriatic agent dithranol with IMQ-TCI to boost vaccination efficacy (Dithranol/IMQ-based transcutane...
Autores principales: | Sohl, Julian, Hartmann, Ann-Kathrin, Hahlbrock, Jennifer, Bartneck, Joschka, Stassen, Michael, Klein, Matthias, Bros, Matthias, Grabbe, Stephan, Marini, Federico, Woods, Kevin, Guezguez, Borhane, Mack, Matthias, Schild, Hansjörg, Muth, Sabine, Melchior, Felix, Probst, Hans Christian, Langguth, Peter, Radsak, Markus P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509335/ https://www.ncbi.nlm.nih.gov/pubmed/36153349 http://dx.doi.org/10.1038/s41541-022-00530-9 |
Ejemplares similares
-
Author Correction: Dithranol as novel co-adjuvant for non-invasive dermal vaccination
por: Sohl, Julian, et al.
Publicado: (2023) -
Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection
por: Hartmann, Ann-Kathrin, et al.
Publicado: (2023) -
Tumor-infiltrating CCR2(+) inflammatory monocytes counteract specific immunotherapy
por: Bartneck, Joschka, et al.
Publicado: (2023) -
Systemically
Administered TLR7/8 Agonist and Antigen-Conjugated
Nanogels Govern Immune Responses against Tumors
por: Stickdorn, Judith, et al.
Publicado: (2022) -
CD27 expression on Treg cells limits immune responses against tumors
por: Muth, Sabine, et al.
Publicado: (2021)